Inflammatory Markers Differentiate Cerebral Venous Sinus Thrombosis from Mimics
Thrombosis and Haemostasis · 01.03.2023 · 123 (03) · 326-335
DOI: 10.1055/a-1951-3402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2023. Verfasst von Jiayue Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Interleukin-6, Sinus Thrombosis, Intracranial. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Imaging tests always misdiagnose anatomical variants of cerebral sinuses as cerebral venous sinus thrombosis (CVST). Anatomical variants of cerebral sinuses are called CVST mimics. This study aimed to identify the role of inflammatory markers in differentiating CVST from mimics. A total of 146 patients diagnosed as CVST and 93 patients with mimics were recruited in this study. Receiver operating characteristic (ROC) analysis was performed to demonstrate the sensitivity and specificity of inflammatory markers for diagnosing CVST. Rank logistic regression analysis was performed to identify the association of markers to CVST severity and prognosis. CVST presented higher inflammatory reactions compared with mimics, demonstrated by the neutrophil count (5.11 [3.97–6.80] vs. 3.06 [2.34–3.86]), interleukin (IL)-6 (7.42 [3.85–14.22] vs. 2.47 [1.50–4.00]), and neutrophil-to-lymphocyte ratio (NLR; 3.19 [2.18–4.62] vs. 1.66 [1.16–2.22]). ROC analysis showed markers with area under the curve (AUC) >0.8, including IL-6 (optimal cutoff: 3.790; kappa value: 0.499), neutrophil count (3.975; 0.522), and NLR (2.070; 0.476). After propensity score matching, only IL-6 had an AUC >0.8, with an optimal cutoff of 3.060 and a kappa value of 0.636. Ranked logistic regression showed that IL-6 (odds ratio, 95% confidence interval: 1.063, 1.026–1.101; 1.029, 1.009–1.050), cerebrospinal fluid (CSF) immunoglobulin (Ig) A (0.279, 0.110–0.706; 0.398, 0.162–0.974), CSF IgM (22.399, 3.004–167.001; 9.545, 1.382–65.928), and CSF IgG (1.287, 1.124–1.473; 1.232, 1.091–1.392) were independently correlated with the baseline and follow-up mRS. In conclusion, inflammatory markers in CVST were different from those in mimics. These markers, especially IL-6, could not only differentiate CVST from its mimics, but also evaluate CVST severity and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China.
- Department of Neurology, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi, People's Republic of China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Natural Science Foundation of Tianjin City
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Ding, J., Pan, L., Lan, D., Chen, Z., Wang, Z., Zou, M., & Meng, R. (2023). Inflammatory Markers Differentiate Cerebral Venous Sinus Thrombosis from Mimics. Thrombosis and Haemostasis, 123(03), 326-335. https://doi.org/10.1055/a-1951-3402
Vancouver
Ding J, Pan L, Lan D, Chen Z, Wang Z, Zou M, et al. Inflammatory Markers Differentiate Cerebral Venous Sinus Thrombosis from Mimics. Thrombosis and Haemostasis. 2023;123(03):326-335. doi:10.1055/a-1951-3402
BibTeX
@article{Ding2023,
author = {Ding, Jiayue and Pan, Liqun and Lan, Duo and Chen, Zhiying and Wang, Zhongao and Zou, Ming and Meng, Ran},
title = {Inflammatory Markers Differentiate Cerebral Venous Sinus Thrombosis from Mimics},
journal = {Thrombosis and Haemostasis},
year = {2023},
volume = {123},
number = {03},
pages = {326--335},
doi = {10.1055/a-1951-3402}
}
EUVIMED